Product name |
enoxacin |
Appearance |
White powder |
Cas number |
74011-58-8 |
MF |
C15H17FN4O3 |
Enoxacin is a broad-spectrum quinolone antibiotic developed by Dainippon Pharmaceutical Co., LTD. It was first approved for marketing in Japan in 1986. It causes bacterial death by acting on the A subunit of bacterial DNA helicase, which inhibits DNA synthesis and replication. This product has a broad spectrum antibacterial action, especially against aerobic gram-negative bacilli with high antibacterial activity, and has a good antibacterial action against the following bacteria in vitro: most bacteria of the Enterobacteriaceae, including citrobacter, Clostridium, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Often has the antibacterial activity Chemicalbook to multi - drug - resistant bacteria. The penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella all had high antibacterial activity. It has antibacterial effect on most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, but only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic streptococcus and Enterococcus faecalis. It has good antimicrobial action against Chlamydia trachomatis, Mycoplasma and Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and Mycobacterium atypical. Poor antibacterial activity against anaerobic bacteria. Clinical for the treatment of various bacterial viruses caused by urinary, reproductive system, respiratory tract, digestive system, skin soft tissue, ear, nose, throat and eye infections.